Evidence map›Paper›PMID 38544254›Full record

ArticleSensors (Basel, Switzerland)2024

Dynamic Measurement of a Cancer Biomarker: Towards In Situ Application of a Fiber-Optic Ball Resonator Biosensor in CD44 Protein Detection.

Zhuldyz Myrkhiyeva, Kanagat Kantoreyeva, Aliya Bekmurzayeva, Anthony W Gomez, Zhannat Ashikbayeva, Meruyert Tilegen, Tri T Pham, Daniele Tosi

Abstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhuldyz MyrkhiyevaLaboratory of Biosensors and Bioinstruments, National Laboratory Astana, Nazarbayev University, 010000 Astana, Kazakhstan.
Kanagat KantoreyevaDepartment of Electrical and Computer Engineering, School of Engineering and Digital Sciences, Nazarbayev University, 010000 Astana, Kazakhstan.
Aliya BekmurzayevaLaboratory of Biosensors and Bioinstruments, National Laboratory Astana, Nazarbayev University, 010000 Astana, Kazakhstan.ORCID 0000-0002-2780-1006
Anthony W GomezLaboratory of Biosensors and Bioinstruments, National Laboratory Astana, Nazarbayev University, 010000 Astana, Kazakhstan.
Zhannat AshikbayevaLaboratory of Biosensors and Bioinstruments, National Laboratory Astana, Nazarbayev University, 010000 Astana, Kazakhstan.ORCID 0000-0001-9057-5876
Meruyert TilegenDepartment of Biology, School of Sciences and Humanities, Nazarbayev University, 010000 Astana, Kazakhstan.
Tri T PhamDepartment of Biology, School of Sciences and Humanities, Nazarbayev University, 010000 Astana, Kazakhstan.ORCID 0000-0003-1026-2146
Daniele TosiLaboratory of Biosensors and Bioinstruments, National Laboratory Astana, Nazarbayev University, 010000 Astana, Kazakhstan.ORCID 0000-0002-6500-4964

Funding

Nazarbayev University 021220FD4451Nazarbayev University 20122022FD4134Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan AP14869161
6 · The paper itself

Abstract

The accuracy and efficacy of medical treatment would be greatly improved by the continuous and real-time monitoring of protein biomarkers. Identification of cancer biomarkers in patients with solid malignant tumors is receiving increasing attention. Existing techniques for detecting cancer proteins, such as the enzyme-linked immunosorbent assay, require a lot of work, are not multiplexed, and only allow for single-time point observations. In order to get one step closer to clinical usage, a dynamic platform for biosensing the cancer biomarker CD44 using a single-mode optical fiber-based ball resonator biosensor was designed, constructed and evaluated in this work. The main novelty of the work is an in-depth study of the capability of an in-house fabricated optical fiber biosensor for in situ detection of a cancer biomarker (CD44 protein) by conducting several types of experiments. The main results of the work are as follows: (1) Calibration of the fabricated fiber-optic ball resonator sensors in both static and dynamic conditions showed similar sensitivity to the refractive index change demonstrating its usefulness as a biosensing platform for dynamic measurements; (2) The fabricated sensors were shown to be insensitive to pressure changes further confirming their utility as an in situ sensor; (3) The sensor's packaging and placement were optimized to create a better environment for the fabricated ball resonator's performance in blood-mimicking environment; (4) Incubating increasing protein concentrations with antibody-functionalized sensor resulted in nearly instantaneous signal change indicating a femtomolar detection limit in a dynamic range from 7.1 aM to 16.7 nM; (5) The consistency of the obtained signal change was confirmed by repeatability studies; (6) Specificity experiments conducted under dynamic conditions demonstrated that the biosensors are highly selective to the targeted protein; (7) Surface morphology studies by AFM measurements further confirm the biosensor's exceptional sensitivity by revealing a considerable shift in height but no change in surface roughness after detection. The biosensor's ability to analyze clinically relevant proteins in real time with high sensitivity offers an advancement in the detection and monitoring of malignant tumors, hence improving patient diagnosis and health status surveillance.

Indexed as

Biosensing TechniquesNeoplasmsBiomarkers, TumorFiber Optic TechnologyHumansHyaluronan ReceptorsOptical FibersProteinsBiomarkers, TumorCD44 protein, humanHyaluronan ReceptorsProteinsball resonatorcancer biomarkerCD44dynamic measurementin vitro detection optical fiber biosensor

Identifiers

PMID38544254
PMCPMC10974573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.